Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter
CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions Ophthalmology Times Source: Author: | Date: 2025-08-27 13:49:00 Source: Author: | Date: 2025-08-27 13:49:00

In advance of the upcoming CCOI Myopia Workshop, scheduled for September 8 in Paris, France, Michael X. Repka, MD, MBA—program co-chair of the event and current president of the American Academy of Ophthalmology—spoke about the challenges and opportunities facing the…
One-Year Clinical Data: Opus Genetics’ Revolutionary Gene Therapy for Inherited Retinal Disease at Global Forums Stock Titan Source: Author: | Date: 2025-08-27 12:00:00 Source: Author: | Date: 2025-08-27 12:00:00

(Image Credit: AdobeStock/Alessandro Grandini) Dry eye disease (DED), as defined by the Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II), is a multifactorial disease of the ocular surface. It is characterized by a loss of…
Workshop held for health experts on children’s eye care Vietnam+ (VietnamPlus) Source: Author: | Date: 2025-08-27 07:47:00 Source: Author: | Date: 2025-08-27 07:47:00
Q&A: Daniela Ferrara on the potential of AI in retina Modern Retina Source: Author: | Date: 2025-08-26 22:49:00 Source: Author: | Date: 2025-08-26 22:49:00
College Partners with Carolina Eye for Certificate Program The Pilot Newspaper Source: Author: | Date: 2025-08-26 19:41:00 Source: Author: | Date: 2025-08-26 19:41:00
identifeye HEALTH launches retinal screening platform Ophthalmology Times Source: Author: | Date: 2025-08-26 18:19:00 Source: Author: | Date: 2025-08-26 18:19:00

Demonstration of the identifeye HEALTH device in use. Photo owned by identifeye HEALTH and used with permission identifeye HEALTH has launched its retinal screening platform and is now delivering results to patients through clinics and community programs. The platform is…

(Image Credit: AdobeStock) The first patient has been dosed in Qlaris Bio’s Phase II Nightingale clinical trial for QLS-111 in patients with normal tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s…